The National Institute of Allergy and Infectious Diseases (NIAID) is seeking information regarding efforts to develop therapeutic products that demonstrate activity for the treatment of diseases on the NIAID Category A, B and C Priority Pathogens list.
Candidate products of interest are those with broad spectrum therapeutic activity against viruses or bacterial pathogens and promising anti-toxins as therapeutic products.
Organizations are invited to submit a white paper describing their research efforts to develop any of the following:
- Products with in vitro and in vivo activity against two or more of the following bacterial pathogens: Bacillus anthracis, Francisella tularensis, Yersinia pestis, Burkholderia pseudomallei, B. mallei, Rickettsia prowazekii and including urgent, serious and concerning drug-resistant bacterial threats as outlined by the CDC.
- Products with in vitro and in vivo activity against two or more of the following viral pathogens: Ebola virus, Marburg virus, Variola major, Dengue virus, Chikungunya virus, MERS Coronavirus, and Influenza virus, including activity against discrete strains, species or serotypes within a virus genus.
- Products with in vitro or in vivo activity against ricin toxin.
The RFI supports the NIAID Division of Microbiology and Infectious Diseases (DMID) in their mission to advance the development of new medical countermeasures against biological agents that are most likely to be used in a terror attack on civilian populations as well as emerging and re-emerging infectious diseases such as MERS, Ebola Virus Disease, antibiotic resistant bacterial infections and pandemic influenza.
Further details are available via Solicitation Number: HHS-NIH-NIAID-BAA-15-037. Responses are due March 13, 2015.
